Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib : A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)
Copyright © 2023 Elsevier Inc. All rights reserved..
BACKGROUND: The addition of neutrophil to lymphocyte ratio (NLR) and bone metastases to the IMDC classification provided by the Meet-URO score, resulted in higher prognostic accuracy in metastatic renal cell carcinoma (mRCC) patients receiving ≥2nd line nivolumab or cabozantinib in 2 retrospective analyses and 1st line nivolumab-ipilimumab in an expanded access programme. Prognostic estimates for older mRCC patients might be key for clinical decision-making.
METHODS: The outcome of real-world older (≥70 years) mRCC patients treated with any line cabozantinib within the multicenter observational prospective ZEBRA (Meet-URO 9) study was analyzed according to the baseline Meet-URO score. The primary endpoint was overall survival (OS). The discriminative ability by Harrell's c-index and calibration were assessed to compare the Meet-URO and IMDC scores.
RESULTS: A total of 104 mRCC patients received cabozantinib as 1st (38%), 2nd (20%), or ≥3rd (41%) line. With a median follow-up of 11.2 months, the median OS (mOS) was of 18.4 months. According to the IMDC score, favorable (15%), intermediate (65%) and poor-risk (19%) patients had a mOS not reached, of 15.6 and 5.7 months respectively (p = .011). According to the Meet-URO score groups, mOS was not reached in both group 1 (10%) and group 2 (25%), while in group 3 (33%), group 4 (25%) and group 5 (8%) mOS was of 13.6, 12.5, and 3.7 months, respectively (p < .001). The discriminative ability of the Meet-URO score was maintained by merging groups 1 to 2 vs. 3 to 4 vs. 5 (p < .001). The Meet-URO score (with either the original 5-group stratification or the modified 3-group one) showed higher accuracy than the IMDC score (c-index of 0.686 and 0.676 vs. 0.622).
CONCLUSION: This analysis confirmed the prognostic accuracy of the Meet-URO score in older mRCC patients treated with cabozantinib and its role as a convenient tool for informing the patient and clinical decisions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Clinical genitourinary cancer - 22(2024), 2 vom: 11. Apr., Seite 126-133.e2 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Damassi, Alessandra [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 09.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clgc.2023.10.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364240148 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364240148 | ||
| 003 | DE-627 | ||
| 005 | 20240410232252.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clgc.2023.10.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM364240148 | ||
| 035 | |a (NLM)37932204 | ||
| 035 | |a (PII)S1558-7673(23)00223-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Damassi, Alessandra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib |b A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 09.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: The addition of neutrophil to lymphocyte ratio (NLR) and bone metastases to the IMDC classification provided by the Meet-URO score, resulted in higher prognostic accuracy in metastatic renal cell carcinoma (mRCC) patients receiving ≥2nd line nivolumab or cabozantinib in 2 retrospective analyses and 1st line nivolumab-ipilimumab in an expanded access programme. Prognostic estimates for older mRCC patients might be key for clinical decision-making | ||
| 520 | |a METHODS: The outcome of real-world older (≥70 years) mRCC patients treated with any line cabozantinib within the multicenter observational prospective ZEBRA (Meet-URO 9) study was analyzed according to the baseline Meet-URO score. The primary endpoint was overall survival (OS). The discriminative ability by Harrell's c-index and calibration were assessed to compare the Meet-URO and IMDC scores | ||
| 520 | |a RESULTS: A total of 104 mRCC patients received cabozantinib as 1st (38%), 2nd (20%), or ≥3rd (41%) line. With a median follow-up of 11.2 months, the median OS (mOS) was of 18.4 months. According to the IMDC score, favorable (15%), intermediate (65%) and poor-risk (19%) patients had a mOS not reached, of 15.6 and 5.7 months respectively (p = .011). According to the Meet-URO score groups, mOS was not reached in both group 1 (10%) and group 2 (25%), while in group 3 (33%), group 4 (25%) and group 5 (8%) mOS was of 13.6, 12.5, and 3.7 months, respectively (p < .001). The discriminative ability of the Meet-URO score was maintained by merging groups 1 to 2 vs. 3 to 4 vs. 5 (p < .001). The Meet-URO score (with either the original 5-group stratification or the modified 3-group one) showed higher accuracy than the IMDC score (c-index of 0.686 and 0.676 vs. 0.622) | ||
| 520 | |a CONCLUSION: This analysis confirmed the prognostic accuracy of the Meet-URO score in older mRCC patients treated with cabozantinib and its role as a convenient tool for informing the patient and clinical decisions | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Elderly | |
| 650 | 4 | |a Prognostic factors | |
| 650 | 4 | |a Prognostic score | |
| 650 | 4 | |a Renal Carcinoma | |
| 650 | 4 | |a Tyrosine kinase inhibitor | |
| 650 | 7 | |a cabozantinib |2 NLM | |
| 650 | 7 | |a 1C39JW444G |2 NLM | |
| 650 | 7 | |a Nivolumab |2 NLM | |
| 650 | 7 | |a 31YO63LBSN |2 NLM | |
| 650 | 7 | |a Anilides |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 700 | 1 | |a Cremante, Malvina |e verfasserin |4 aut | |
| 700 | 1 | |a Signori, Alessio |e verfasserin |4 aut | |
| 700 | 1 | |a Rebuzzi, Sara Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Fornarini, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Giudice, Giulia Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Maruzzo, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Procopio, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Sorarù, Mariella |e verfasserin |4 aut | |
| 700 | 1 | |a Di Napoli, Marilena |e verfasserin |4 aut | |
| 700 | 1 | |a Fratino, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Santini, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Grillone, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Ballestrin, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Dionese, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Nasso, Cecilia |e verfasserin |4 aut | |
| 700 | 1 | |a Catalano, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Murianni, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Rescigno, Pasquale |e verfasserin |4 aut | |
| 700 | 1 | |a Anpalakhan, Shobana |e verfasserin |4 aut | |
| 700 | 1 | |a Banna, Giuseppe Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Basso, Umberto |e verfasserin |4 aut | |
| 700 | 1 | |a Buti, Sebastiano |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical genitourinary cancer |d 2005 |g 22(2024), 2 vom: 11. Apr., Seite 126-133.e2 |w (DE-627)NLM160229936 |x 1938-0682 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2024 |g number:2 |g day:11 |g month:04 |g pages:126-133.e2 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clgc.2023.10.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2024 |e 2 |b 11 |c 04 |h 126-133.e2 | ||